Elite Health Systems Inc.

11/20/2026 | Press release | Distributed by Public on 11/20/2026 11:58

Quarterly Report for Quarter Ending September 30, 2026 (Form 10-Q)

Management Discussion and Analysis of Financial Condition and Results of Operations.

Critical Accounting Policies

The Condensed Consolidated Financial Statements of Elite Health Systems Inc. and subsidiaries (the "Company") have been prepared in accordance with accounting principles generally accepted in the United States of America. As such, some accounting policies have a significant impact on amounts reported in the Condensed Consolidated Financial Statements. A summary of those significant accounting policies can be found in Note B to the Consolidated Financial Statements, in our 2025 Annual Report on Form 10-K. In particular, judgment is used in areas such as determining and assessing possible asset impairments, including investments in, and advances, to unconsolidated entities.

The following discussion and analysis provides information which the Company's management believes is relevant to an assessment and understanding of the Company's results of operations and financial condition. This discussion should be read in conjunction with the Condensed Consolidated Financial Statements and notes thereto appearing elsewhere herein.

Recent events

None

Results of Operations

Three Months ended September 30, 2026, Compared to Three Months Ended September 30, 2025

Revenue related to Medicare Advantage payments from CMS was $179,000 and $0, for the three months ended September 30, 2026, and 2025, respectively. The amount in 2026 was due to the fact that Elite began serving Medicare Advantage policy holders in 2026. Policy expenses for the same period was $194,000 and $0 respectively, primarily due to medical and capitated payments associated with serving Medicare Advantage policy holders.

Revenue attributed to services was $1,097,000 and $0 for the three months ended September 30, 2026, and 2025, respectively due to the acquisition of PSS. Cost of revenue related to services for the same period was $953,000 and $0, respectively.

Selling, general, and administrative expenses of $1,386,000 for the third quarter of 2026 were 19% higher than the $1,165,000 incurred during the comparable period in 2025, due mostly to the continued investment in Elite.

During the three months ended September 30, 2026 and 2025, the Company recorded no income tax benefit or provision.

For the three months ended September 30, 2026, the Company reported a net loss of $1,486,000 as compared to $1,161,000 for the same period a year earlier. The net loss was primarily due to the continued investment in Elite above the generation of any revenue.

Nine months ended September 30, 2026, Compared to Nine months ended September 30, 2025

Revenue related to Medicare Advantage payments from CMS was $513,000 and $0, for the nine months ended September 30, 2026, and 2025 respectively. The amount in 2026 was due to the fact that Elite began serving Medicare Advantage policy holders in 2026. Medical and capitated expenses for the same period was $581,000 and $0 respectively, also due to serving Medicare Advantage policy holders.

Revenue attributed to services was $3,470,000 and $0 for the nine months ended September 30, 2026, and 2025, respectively due to the acquisition of PSS. Cost of revenue related to services for the same period was $3,569,000 and $0, respectively.

Selling, general, and administrative expenses of $4,511,000 for the nine months ended September 30, 2026, were 122% higher than the $2,036,000 incurred during the comparable period in 2025, due mostly to the acquisition of PSS and an increase in cost at EHP now that the health plan is operating.

During the nine months ended September 30, 2026 and 2025 the Company recorded no income tax benefit or provision.

For the nine months ended September 30, 2026, the Company reported a net loss of $4,312,000 compared to $2,026,000 for the same period a year earlier. The net loss was primarily due to the acquisition of PSS.

Liquidity and Capital Resources

The Company's primary sources of liquidity are from equity transactions discussed below.

Net cash used in operating activities for the nine months ended September 30, 2026, was $4,035,000 as compared to $1,448,000 for the same period a year earlier. This change is primarily due to the Company's acquisition of PSS and higher expenses of EHP now that the plan has begun operations. The Company used cash in investing activities for the nine months ended September 30, 2026 and 2025 of $13,000 and $981,000, respectively, due primarily to purchases of fixed assets and development costs.

The Company raised total proceeds from the issuance of common stock, warrants and notes payable of an aggregate of $1,030,000 and $2,365,000 during the nine months ended September 30, 2026 and 2025, respectively. As a result of these issuances, as of September 30, 2026, there were outstanding 28,682,988 shares of the Company's Common Stock. In addition, the Company issued subordinated notes payable and attached common stock warrants to the Company's CEO of an aggregate of $850,000 during the quarter ended September 30, 2026 compared to $0 during the same period in 2025.

For this sale of securities in connection with private placement, no general solicitation was used, no commissions were paid, all participants in the private placement were accredited investors, and the Company relied on the exemption from registration available under Section 4(a)(2) and/or Rule 506(b) of Regulation D promulgated under the Securities Act with respect to transactions by an issuer not involving any public offering.

The Company presently intends to use the net proceeds from the private placement principally to execute the plan of Elite Health to establish a managed care organization that will operate as a Medicare Advantage plan for seniors.

The Company presently intends to use the net proceeds from the private placement principally to execute the plan of Elite Health to establish a managed care organization that will operate as a Medicare Advantage plan for seniors.

In the nine months ended September 30, 2026, the Company incurred a net loss of $4,312,000 compared to $2,026,000 in the same period of fiscal year 2025. The Company has received state and Federal approval to operate as a Medicare Advantage plan and began operating as a Medicare Advantage plan on January 1, 2026. As a result, it recorded no revenue from its health plan in 2025 and has significant expenses. The Company has funded operations through the sale of common stock. The Company had an accumulated deficit in stockholders' equity of $16,561,000 and $12,249,000 at September 30, 2026 and December 31, 2025, respectively; cash and cash equivalents of $740,000 and $3,758,000 at September 30, 2026 and December 31, 2025, respectively; and working capital of $136,000 and $3,144,000 at September 30, 2026 and December 31,2025, respectively. In addition, the Company currently does not have access to capital through a line of credit nor other readily available sources of capital. Together, these factors raised substantial doubt regarding the Company's ability to continue as a going concern at September 30, 2026.

However, management has considered its plans to continue the Company as a going concern, concentrating on the establishment and operation of managed health care plans. The Company raised gross proceeds of approximately $14 million in support of this business opportunity through the sale of its Common Stock in a private placement and believes it has access to additional capital in 2026. However, the Company is operating in a highly competitive business environment with complex regulatory and operational challenges. In order to be successful, the Company must significantly increase its health care membership and hire additional key members of management, both of which will take significant capital and time. As a result, the Board of Directors authorized management to consider and pursue strategic alternatives involving the Company. The strategic review authorized by the Company's Board of Directors will include consideration of potential equity or debt capital, selling certain assets, including one or more of its operating businesses, or other strategic financings or transactions, such as a merger or disposition of all of its assets. No timetable has been established to achieve any transaction and there can be no assurance that any strategic transaction, if implemented, will result or result in an increase in stockholder value. The Company may terminate its review at any time and may ultimately determine not to pursue a strategic transaction.

Management believes its plan alleviates the substantial doubt and that it will be successful in its planned business initiatives and will be able to continue as a going concern through at least the next twelve months. However, failure to consummate a strategic transaction, including a financing, merger, sale or disposition of all or substantially all of its assets, or other strategic alternative, could have a material adverse effect on the Company's liquidity, financial condition and ability to continue operations. There can be no assurance that any such transaction will be completed on acceptable terms, or at all.

Risk Factors

We desire to take advantage of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. The factors listed under the caption "Risk Factors" in Annual Report on our Form 10-K for the fiscal year ended December 31, 2025, have affected or could affect our actual results and could cause such results to differ materially from those expressed in any forward-looking statements made by us. Investors should carefully consider these risks and speculative factors inherent in and affecting our business and an investment in our common stock.

Disclosure Regarding Forward Looking Statements

The Securities and Exchange Commission encourages companies to disclose forward looking information so that investors can better understand a company's future prospects and make informed investment decisions. This document contains such "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, particularly statements anticipating future growth in revenues and cash flow. Words such as "anticipates," "estimates," "expects," "projects," "targets," "intends," "plans," "believes," "will be," "will continue," "will likely result," and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify such forward-looking statements. Those forward-looking statements are based on management's present expectations about future events. As with any projection or forecast, they are inherently susceptible to uncertainty and changes in circumstances, and the Company is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of such changes, new information, future events or otherwise.

The Company operates in a highly competitive and rapidly changing environment and in businesses that are dependent on our ability to: achieve profitability; increase revenues; sustain our current level of operations; maintain satisfactory relations with business partners; attract and retain key personnel; maintain and expand our strategic alliances; and protect our intellectual property. The Company's actual results could differ materially from management's expectations because of changes in such factors. New risk factors can arise and it is not possible for management to predict all such risk factors, nor can it assess the impact of all such risk factors on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results. Factors that could cause actual results to differ materially from those currently anticipated include the following:

●

Uncertainties relating to our ability to successfully implement our strategy of developing a Medicare Advantage plan under our Elite Health subsidiaries;

●

Uncertainty over our ability to achieve a Medicare Advantage license in California in a timely manner, acquire managed health consumers in California, expand consumer enrollment beyond this initial state, or diversify and expand our portfolio of products and services, our business and results of operations will be significantly impaired;

●

Our ability to raise capital in the future on satisfactory terms;

●

Our financial condition and liquidity;

●

Uncertainty over our ability to successfully implement management's plan to improve liquidity, including the ability to manage costs, systems and growth;

All forward looking statements should be considered in the context of the risks and other factors described above and in "Risk Factors" (Part I, Item 1A of the Company's Annual Report on Form 10-K for the Fiscal Year ended December 31, 2025), "Quantitative and Qualitative Disclosures about Market Risk" (Part II, Item 7A of the Company's Annual Report on Form 10-K for the Fiscal Year ended December 31, 2025), and "Management's Discussion and Analysis" (Part I, Item 2 of this Form 10-Q). We undertake no obligation to update or revise publicly any forward-looking statements, whether because of new information, future events, or otherwise.

Investors should also be aware that while the Company might, from time to time, communicate with securities analysts, it is against the Company's policy to disclose to them any material non-public information or other confidential commercial information. Accordingly, investors should not assume that the Company agrees with any statement or report issued by any analyst irrespective of the content of the statement or report. Furthermore, the Company has a policy against issuing or confirming financial forecasts or projections issued by others. Thus, to the extent that reports issued by securities analysts or others contain any projections, forecasts or opinions, such reports are not the responsibility of the Company.

In addition, the Company's overall financial strategy, including growth in operations, maintaining financial ratios and strengthening the balance sheet, could be adversely affected by increased interest rates, construction delays or other transactions, economic slowdowns and changes in the Company's plans, strategies and intentions.

Elite Health Systems Inc. published this content on November 20, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on November 20, 2026 at 17:58 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]